145P - Outcomes of treatment of glioblastoma multiforme: A single institution experience from South India

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Central Nervous System Malignancies
Presenter Annu George
Citation Annals of Oncology (2016) 27 (suppl_9): ix42-ix45. 10.1093/annonc/mdw578
Authors A.S. George1, A. Philip2, D. Poorna3, D. Makunny3, A. Pillai4, B. M.r5, R. Pillai2, W. Jose3, K. Pavithran2
  • 1Medical Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 2Medical Oncology, Amrita Institute of Medical Sciences, 682041 - Cochin/IN
  • 3Radiation Oncology, Amrita Institute of Medical Sciences, 682041 - Cochin/IN
  • 4Neurosurgery, Amrita Institute of Medical Sciences, 682041 - Cochin/IN
  • 5Pathology, Amrita Institute of Medical Sciences, 682041 - Cochin/IN

Abstract

Background

Glioblastoma multiforme(GBM) is the most common primary tumor of brain in adults.Radiotherapy (RT)plus concomitant and adjuvant temozolamide treatment is the current standard therapy for newly diagnosed GBM.The aim of our study is to analyse the clinical results and prognostic factors of GBM patients treated by post operative RT and concomitant Temozolamide followed by adjuvant temozolamide in a low income nation.

Methods

We retrospectively evaluated 143 patients with GBM, treated in our institution from April 2006 to June 2015.Demographic and disease characteristics were recorded. Primary endpoint of the study was Overall survival(OS) and secondary endpoint was Progression Free Survival(PFS).OS was studied with respect to various variables including sex, ECOG score, extent of surgery, presentation with or without seizures, and number of adjuvant cycles of temozolamide(

Results

Median age at presentation was 52 years(range 18-77 years).Male to female ratio of 1.74:1.All 143 patients underwent surgery with 22 patients(15.4%)having a biopsy alone,28(19.6%) partial resection and 93(65%) complete resection. All patients received RT, 25 did not complete prescribed 60 Gy either due to toxicity or disease progression. 88.1% received concomitant temozolamide, and 15(10.5%) completed less than 75% of the planned dose of temozolamide due to toxicity. Median OS was 13.8 months(95% CI 10.8 - 16.7).On univariate analysis, sex or seizures at presentation did not affect survival, but better survival outcome was seen with performance status ≤2 (p = 0.011), complete resection(p 

Conclusions

Our single institution experience demonstrates that adherence to globally accepted guidelines for treatment and management of gliobastoma multiforme, gives similar results to that in literature.Good PS, lack of residual disease and completion of 6 cycles of adjuvant temozolamide are factors predicting a favourable outcome.

Clinical trial indentification

Legal entity responsible for the study

Institutional Review Board, Amrita Institute Of Medical Sciences

Funding

Amrita Institute Of Medical Sciences

Disclosure

All authors have declared no conflicts of interest.